Newsroom
Biotech Companies Grant Inducement Awards, Aptevo Therapeutics Announces Reverse Stock Split, Jianzhi Regains Nasdaq...
By KlickAnalytics Data Insights | November 29, 2024 08:02PM ET
Key Points
- Adicet Bio, Cue Biopharma, Sarepta Therapeutics, Verve Therapeutics, 89bio, and IDEAYA Biosciences announce inducement grants to new employees under Nasdaq Listing Rule 5635(c)(4)
- Aptevo Therapeutics plans a 1-for-37 reverse stock split to comply with Nasdaq requirements
- Jianzhi Education Technology regains compliance with Nasdaq Listing Rule 5550(a)(2) after receiving a compliance notice
Adicet Bio, Cue Biopharma, Sarepta Therapeutics, Verve Therapeutics, 89bio, and IDEAYA Biosciences have announced the granting of inducement awards to new employees as per Nasdaq Listing Rule 5635(c)(4). Adicet Bio granted an inducement award to one individual who joined the company in November 2024. The award consists of non-qualified stock options to purchase 6,000 shares of common stock at an exercise price of $1.13 per share. Cue Biopharma also granted an option award to its interim chief development officer, Dr. Daniel Baker, with approval from independent directors. Sarepta Therapeutics awarded equity incentives to 14 new employees under its Employment Commencement Incentive Plan. Verve Therapeutics and 89bio also announced equity awards to new hires, while IDEAYA Biosciences granted non-qualified stock options to a newly hired employee.
In other news, Aptevo Therapeutics revealed plans for a 1-for-37 reverse stock split to bring its outstanding shares of common stock in compliance with Nasdaq regulations. The reverse stock split is scheduled to take effect on December 3, 2024, at 5:01 p.m. This strategic move aims to align Aptevo's stock price with Nasdaq's requirements.
Furthermore, Jianzhi Education Technology Group Company Limited received positive news from Nasdaq after regaining compliance with Nasdaq Listing Rule 5550(a)(2). The Company received a Compliance Notice from Nasdaq, dated November 27, 2024, confirming its compliance with the Minimum Bid Price Requirement. This development showcases Jianzhi's commitment to meeting Nasdaq's listing standards and maintaining regulatory compliance.
The biotechnology industry continues to witness significant developments as companies like Adicet Bio, Cue Biopharma, Sarepta Therapeutics, Verve Therapeutics, 89bio, and IDEAYA Biosciences provide inducement grants to new employees under Nasdaq regulations. At the same time, Aptevo Therapeutics prepares for a reverse stock split to meet Nasdaq requirements, while Jianzhi Education Technology successfully regains compliance with Nasdaq rules. These actions demonstrate the proactive measures taken by companies to ensure regulatory adherence and strengthen their positions in the market.
For more information:
Ask the market a question. Get a calculated answer.
The AI is not a chatbot bolted onto a document store. It calls the same analytics engine that powers every screen on this platform — so what comes back is a number it computed from raw history, with the command that produced it.
86,000+ instruments
Global equities, ETFs, funds, options, FX, commodities, crypto, economics, filings, transcripts and news — one normalised symbol universe with adjusted history.
A real analytics engine
Screening, backtesting, technicals, options analytics, correlations, seasonality and factor models — computed on demand from raw prices, never a stale cache.
It shows its working
Answers arrive with the charts, tables and tool calls behind them, so you can check the number instead of trusting a paraphrase.
Your own documents
Upload filings, decks and research. Ask across them and the answer cites the page it came from.
Agents and workflows
Multi-step research that runs the platform's tools for you — screen, pull the history, compute, compare, then write it up.
MCP, CLI and API
The same command catalogue from Claude, your own agent, a shell or your pipeline. The answer on screen is the answer your job gets at 4am.
You ask
“How does NVDA usually trade through earnings?”
It calls
→ ka.options_expected_move(NVDA)
It answers
NVDA has averaged a 9.2% absolute move on the day after earnings and closed higher 67% of the time. Two in three reactions land between −4.2% and +16.3% — the distribution is skewed right, not symmetric.
Every figure computed live from our own history — not scraped, not summarised.
Or start with